Loading organizations...
§ Private Profile · Palo Alto, CA, USA
Biopharmaceutical company develops therapeutic antibodies for cancer immunotherapy, targeting immune-suppressive cells.
Immune-Onc Therapeutics, based in Palo Alto, California, develops innovative therapeutic antibodies for cancer immunotherapy, specifically targeting immune-suppressive cells within the tumor microenvironment. The clinical-stage company advances novel immuno-oncology products from discovery to clinical stages, aiming to mobilize the host's systemic immunity. It has secured $7 million in Series A financing to support its antibody discovery and development efforts, which include products licensed from institutions like Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center. Key leadership includes Chief Medical Advisor Barbara Klencke, Chief Development Officer Hong Xiang, and Scientific Advisory Board Chair Michael Karin. Immune-Onc Therapeutics was founded in 2016 by Charlene Liao and Guo-Liang Yu. Its business model centers on venture-funded biopharmaceutical company, raises capital through equity financings like Series A to support antibody discovery and development.
Immune-Onc Therapeutics has raised $138.0M across 4 funding rounds.
Immune-Onc Therapeutics has raised $138.0M in total across 4 funding rounds.
Immune-Onc Therapeutics has raised $138.0M in total across 4 funding rounds.
Immune-Onc Therapeutics's investors include Proxima Ventures, The Leukemia & Lymphoma Society, WuXi Healthcare Ventures, Dave Chenn, Northern Light Venture Capital, Octagon Capital, Sphera Healthcare, Vivo Capital, Stanford.
Immune-Onc Therapeutics has raised $138.0M across 4 funding rounds. Most recently, it raised $25.0M Series B Extension in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 5, 2023 | $25M Series B Plus | — | Proxima Ventures, The Leukemia & Lymphoma Society, WuXi Healthcare Ventures | Announced |
| Mar 30, 2021 | $73M Series B | Dave Chenn | Northern Light Venture Capital, Octagon Capital, Sphera Healthcare, The Leukemia & Lymphoma Society, Vivo Capital | Announced |
| Sep 18, 2018 | $33M Series B | — | Northern Light Venture Capital, Stanford, Vivo Capital | Announced |
| Sep 6, 2016 | $7M Series A | — | — | Announced |